|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.93 EUR | +0.22% |
|
+2.02% | +2.87% |
| 07-09 | Federal and state governments wrangle over health savings package | DP |
| 07-07 | FMC FRESENIUS MEDICAL CARE AG : Receives a Sell rating from JP Morgan | ZD |
| Fiscal Period: December | 2016 | 2017 (EUR) | 2018 (EUR) | 2019 (EUR) | 2020 (EUR) | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) | 2025 (EUR) |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 17.62B | 19.4B | 19.45B | 19.34B | 19.63B | |||||
Total Revenues | 17.62B | 19.4B | 19.45B | 19.34B | 19.63B | |||||
Cost of Goods Sold, Total | 12.54B | 14.09B | 14.53B | 14.58B | 14.6B | |||||
Gross Profit | 5.08B | 5.31B | 4.93B | 4.76B | 5.03B | |||||
Selling General & Admin Expenses, Total | 3.01B | 3.51B | 3.2B | 3.14B | 3.03B | |||||
Provision for Bad Debts | - | - | - | - | - | |||||
R&D Expenses | 221M | 229M | 232M | 183M | 158M | |||||
Other Operating Expenses | - | - | -26.86M | -109M | -31.65M | |||||
Other Operating Expenses, Total | 3.23B | 3.73B | 3.4B | 3.22B | 3.16B | |||||
Operating Income | 1.84B | 1.58B | 1.52B | 1.54B | 1.87B | |||||
Interest Expense, Total | -354M | -360M | -425M | -407M | -384M | |||||
Interest And Investment Income | 73.17M | 67.66M | 88.22M | 71.58M | 69.61M | |||||
Net Interest Expenses | -280M | -292M | -336M | -335M | -315M | |||||
Income (Loss) On Equity Invest. | 92.18M | 66.56M | 122M | 135M | 181M | |||||
Currency Exchange Gains (Loss) | - | - | -35.5M | -23.06M | -43.79M | |||||
EBT, Excl. Unusual Items | 1.66B | 1.35B | 1.27B | 1.32B | 1.69B | |||||
Restructuring Charges | -62.86M | -190M | -260M | -317M | -104M | |||||
Merger & Related Restructuring Charges | - | -24.37M | - | - | - | |||||
Impairment of Goodwill | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Investments | - | 148M | 14.67M | 44.03M | -77.04M | |||||
Gain (Loss) On Sale Of Assets | - | - | 4.84M | 14.66M | 993K | |||||
Asset Writedown | -36.55M | -118M | - | - | - | |||||
Other Unusual Items | 15.43M | 53.56M | - | - | - | |||||
EBT, Incl. Unusual Items | 1.57B | 1.22B | 1.03B | 1.06B | 1.51B | |||||
Income Tax Expense | 353M | 325M | 301M | 316M | 321M | |||||
Earnings From Continuing Operations | 1.22B | 894M | 732M | 741M | 1.19B | |||||
Net Income to Company | 1.22B | 894M | 732M | 741M | 1.19B | |||||
Minority Interest | -250M | -221M | -233M | -203M | -213M | |||||
Net Income - (IS) | 969M | 673M | 499M | 538M | 978M | |||||
Net Income to Common Incl Extra Items | 969M | 673M | 499M | 538M | 978M | |||||
Net Income to Common Excl. Extra Items | 969M | 673M | 499M | 538M | 978M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 3.31 | 2.3 | 1.7 | 1.83 | 3.36 | |||||
Basic EPS - Continuing Operations | 3.31 | 2.3 | 1.7 | 1.83 | 3.36 | |||||
Basic Weighted Average Shares Outstanding | 293M | 293M | 293M | 293M | 291M | |||||
Net EPS - Diluted | 3.31 | 2.3 | 1.7 | 1.83 | 3.36 | |||||
Diluted EPS - Continuing Operations | 3.31 | 2.3 | 1.7 | 1.83 | 3.36 | |||||
Diluted Weighted Average Shares Outstanding | 293M | 293M | 293M | 293M | 291M | |||||
Normalized Basic EPS | 2.68 | 2.12 | 1.92 | 2.11 | 2.9 | |||||
Normalized Diluted EPS | 2.68 | 2.12 | 1.92 | 2.11 | 2.9 | |||||
Dividend Per Share | 1.35 | 1.12 | 1.19 | 1.44 | 1.49 | |||||
Payout Ratio | 40.49 | 58.74 | 65.86 | 64.91 | 43.19 | |||||
American Depositary Receipts Ratio (ADR) | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | |||||
Supplemental Items | ||||||||||
EBITDA | 2.69B | 2.49B | 2.38B | 2.35B | 2.62B | |||||
EBITA | 1.95B | 1.68B | 1.62B | 1.62B | 1.95B | |||||
EBIT | 1.84B | 1.58B | 1.52B | 1.54B | 1.87B | |||||
EBITDAR | 2.77B | 2.57B | 2.47B | 2.43B | 2.7B | |||||
Total Revenues (As Reported) | 17.62B | 19.4B | 19.45B | 19.34B | 19.63B | |||||
Effective Tax Rate - (Ratio) | 22.45 | 26.65 | 29.1 | 29.9 | 21.22 | |||||
Current Domestic Taxes | -11.68M | -5.42M | 20.95M | 69.97M | 45.97M | |||||
Current Foreign Taxes | 297M | 372M | 402M | 319M | 302M | |||||
Total Current Taxes | 286M | 366M | 423M | 389M | 348M | |||||
Deferred Domestic Taxes | 18.4M | 16.96M | 34.02M | -37.76M | 11.03M | |||||
Deferred Foreign Taxes | 48.86M | -58.43M | -156M | -34.91M | -38.24M | |||||
Total Deferred Taxes | 67.26M | -41.47M | -122M | -72.67M | -27.21M | |||||
Normalized Net Income | 785M | 623M | 562M | 619M | 845M | |||||
Interest Capitalized | 4.17M | 2.24M | 2.5M | 2.15M | 1.58M | |||||
Interest on Long-Term Debt | 147M | 154M | 151M | 151M | 145M | |||||
Non-Cash Pension Expense | 11.41M | 11.42M | 23.18M | 23.65M | 23.38M | |||||
Supplemental Operating Expense Items | ||||||||||
Research And Development Expense From Footnotes | 221M | 229M | 232M | 183M | 158M | |||||
Net Rental Expense, Total | 80.26M | 83.64M | 91.98M | 79.5M | 82.29M | |||||
Imputed Operating Lease Interest Expense | 17.88M | 18.28M | 24.86M | 22.55M | 23.3M | |||||
Imputed Operating Lease Depreciation | 62.38M | 65.37M | 67.12M | 56.95M | 58.99M | |||||
Stock-Based Comp., Other (Total) | 28.29M | -5.87M | 32.52M | 38.46M | 45.12M | |||||
Total Stock-Based Compensation | 28.29M | -5.87M | 32.52M | 38.46M | 45.12M |
- Stock Market
- Stocks
- FME Stock
- Financials Fresenius Medical Care AG
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















